N.L.'s new health minister says negotiating a federal pharmacare deal is a top 'priority' - CBC
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Nfld. & LabradorNewfoundland and Labrador’s health minister says reaching a pharmacare deal with the federal government is one of his highest priorities. That comes despite the federal health minister's past statement that deals with other provinces will expire. PCs not giving up on federal pharmacare deal despite past minister's assertion the feds shut the doorMark Quinn · CBC News · Posted: Oct 01, 2026 4:30 AM EDT | Last Updated: October 1Listen to this articleEstimated 4 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Newfoundland and Labrador Health Minister Joedy Wall says signing on to the federal pharmacare program is a priority for the Progressive Conservative government. (Mark Quinn/ CBC)Newfoundland and Labrador's newly appointed health minister says reaching a pharmacare deal with the federal government is one of his highest priorities. "That was one of the top three things that was discussed when I came into the department was the pharmacare program," said Joedy Wall.
This article is an excerpt. To read the full content, visit the original source. CBC
Related articles
Bioengineer.org | Switching HIV drugs or adding zoledronic acid rebuilds bone lost to tenofovir - European AIDS Treatment Group
Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain - ScienceAlert
The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.
0 comments
No comments yet. Be the first to share your thoughts!